Vaccine manufacturers at the BIO international conference in San Diego this week acknowledged a series of once-unthinkable policy shifts under Health Secretary Robert F. Kennedy Jr. — including the cancellation of major mRNA vaccine contracts, the dismantling of universal vaccine recommendations, and cuts to government research funding — yet some told STAT they feel more optimistic than they did a year ago.
What Kennedy Has Changed
Robert F. Kennedy Jr., a longtime critic of vaccines who now serves as health secretary, has overseen disruptions that industry participants describe as unprecedented in recent memory. The cancellation of major mRNA vaccine contracts is the most concrete: those agreements had anchored near-term revenue for manufacturers, and their removal leaves a gap that private demand is unlikely to fill on the same timeline.
The dismantling of universal vaccine recommendations carries perhaps longer-lasting consequences. Universal recommendations — the official schedules that guide clinicians and inform insurance coverage decisions — function as the commercial foundation of the vaccine market. Without them, what gets prescribed, and reimbursed, becomes considerably less predictable.
Cuts to government funding for research represent the third major disruption. Federal investment has historically supported the earliest stages of vaccine development, the work that occurs well before any product reaches clinical trials. Reducing that support shrinks the pool of candidates that might otherwise advance.
The Mood at BIO: Cautious, Not Crushed
Despite cataloguing that damage, some vaccine makers told STAT in San Diego that their outlook has actually improved compared with twelve months ago. They acknowledged the disruptions openly rather than minimizing them, and they conceded that Washington could deliver more changes ahead — an admission that the current environment is not yet settled.
The optimism is notable, though its precise basis is not fully on the record. What is clear is that confidence has not entirely drained from the sector.
What the Next Round of Decisions Will Reveal
The regulatory environment governing vaccines now has fewer fixed points than at any time in recent memory, and those attending the BIO conference acknowledged it. Kennedy's tenure is not over, and the policies most consequential for vaccine makers may not yet have been announced.
Companies that read current conditions as temporary tend to preserve staffing and investment; those that treat them as structural begin to exit. Which interpretation dominates in the coming months will determine whether the infrastructure built around vaccine development in recent years endures — or quietly winds down.